RHEACEL is a subsidiary of TICEBA, developing human pharmaceuticals based on ABCB5+ mesenchymal stem cells. The company uses the GMP-compliant manufacturing process established by TICEBA to expand primary limbal stem cells from corneal tissue donors. Clinical trials using these cells are ongoing in Germany and the US.
Timeline
2012
RHEACELL was founded.
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services